MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeutics
24 mai 2016 01h33 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, May 24, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and The University of Texas MD Anderson Cancer Center today...
MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016
19 mai 2016 01h34 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, May 19, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the publication of three abstracts which were...
MorphoSys to Present at Three Upcoming Conferences
04 mai 2016 05h35 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, May 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
Deutsche Bank 41st Annual...
MorphoSys AG Reports Results for the First Three Months of 2016
03 mai 2016 01h08 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, May 3, 2016 (GLOBE NEWSWIRE) -- Financial Guidance 2016 Confirmed
Conference call and webcast (in English) today at 2:00pm CEST (1:00pm BST/8:00am EDT)
MorphoSys AG...
MorphoSys to Host Q1 2016 Conference Call on May 3, 2016
27 avr. 2016 08h06 HE
|
MorphoSys AG
Martinsried / Munich, Germany, April 27, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months' 2016 results on May 3, 2016 at 7:00 am...
MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
21 avr. 2016 02h03 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Novartis has confirmed that a...
Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
21 avr. 2016 02h01 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Novartis has confirmed that a...
MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on June 2, 2016 according to sec. 121 para. 4a AktG with the objective of Europe-wide distribution
20 avr. 2016 09h32 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 20, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG Martinsried/Planegg Securities Code Number: 663200 ISIN: DE0006632003
Convenience Translation: The text decisive for...
MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis
18 avr. 2016 05h45 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 18, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that its licensing partner GSK has initiated a...
MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106
07 avr. 2016 01h33 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced today that...